To determine potential correlates of immune recovery from AIDS-related cytomegalovirus retinitis (CMVR), multiparameter flow cytometry was used to characterize CMV-specific T cells from subjects with CMVR. Individuals with active retinitis were compared with those who had been clinically immunorestored by antiretroviral therapy and had у2 years of ophthalmologic follow-up without anti-CMV therapy or retinitis reactivation or progression. In comparison with patients with active retinitis, immunorestored patients had higher circulating CD4 + and CD8 + T cells expressing interleukin-2 and interferon-g in response to combined CMV pp65 and IE1 peptide pool stimulation. CD4 + T cell responses were predominantly to pp65, whereas CD8 + T cell responses were predominantly to IE. Immunorestored patients, compared with patients with active retinitis, had increased levels of circulating CMV-specific CD8 + T cells with "early" (CD27 Before the availability of highly active antiretroviral therapy (HAART) regimens, cytomegalovirus (CMV) end-organ disease, primarily retinitis (CMVR), was a common complication of AIDS, occurring in 40% of patients with absolute CD4 + T cell counts !50 cells/mL [1] [2] [3] . Before HAART, retinitis progressed despite systemic anti-CMV drug therapy [4] . CMVR incidence has dropped substantially in Western countries where HAART became widely available [5, 6] , although it sub-
To determine potential correlates of immune recovery from AIDS-related cytomegalovirus retinitis (CMVR), multiparameter flow cytometry was used to characterize CMV-specific T cells from subjects with CMVR. Individuals with active retinitis were compared with those who had been clinically immunorestored by antiretroviral therapy and had у2 years of ophthalmologic follow-up without anti-CMV therapy or retinitis reactivation or progression. In comparison with patients with active retinitis, immunorestored patients had higher circulating CD4 + and CD8 + T cells expressing interleukin-2 and interferon-g in response to combined CMV pp65 and IE1 peptide pool stimulation. CD4 + T cell responses were predominantly to pp65, whereas CD8 + T cell responses were predominantly to IE. Immunorestored patients, compared with patients with active retinitis, had increased levels of circulating CMV-specific CD8 + T cells with "early" (CD27 Before the availability of highly active antiretroviral therapy (HAART) regimens, cytomegalovirus (CMV) end-organ disease, primarily retinitis (CMVR), was a common complication of AIDS, occurring in 40% of patients with absolute CD4 + T cell counts !50 cells/mL [1] [2] [3] . Before HAART, retinitis progressed despite systemic anti-CMV drug therapy [4] . CMVR incidence has dropped substantially in Western countries where HAART became widely available [5, 6] , although it sub-sequently stabilized at ∼25% of its pre-HAART incidence [5] [6] [7] . Most patients with prevalent CMVR whose absolute CD4 + T cell counts were immunorestored by HAART have been able to discontinue anti-CMV therapy without further retinitis progression [8] [9] [10] . Nevertheless, CMVR remains an important complication of AIDS internationally, being reported in up to 8.5% of patients with AIDS in parts of Africa [11] , 15% in Thailand [12] , and 17% in India [13] . Thus, interventions that could prevent or more cost effectively treat CMVR could have worldwide impact.
The ability to differentiate patients at high risk for incident retinitis or progression of prevalent retinitis from those at low risk would allow treatment to be delivered to patients at high risk, whereas those at low risk could be spared the significant drug toxicities and costs associated with long-term anti-CMV treatment. Because CMV-specific T cells may be important in controlling replication of CMV, numerous studies have investigated their role in controlling disease, both in patients with AIDS and in transplant recipients [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . Furthermore, several groups, including ours, have investigated whether CMV-specific T cell responses could potentially be used to inform clinicians when to initiate or discontinue treatment for patients with AIDS with CMVR [14] [15] [16] [17] [18] [19] [20] . Thus, to identify potential immune correlates of protection against AIDS-related CMV end-organ disease that might subsequently be tested for clinical utility in patients at risk for developing AIDS-related CMVR or progression of prevalent CMVR, we measured the frequency of CMV-specific, interferon (IFN)-g-and interleukin (IL)-2-expressing CD4 + and CD8 + T cells by cytokine flow cytometry (CFC) and simultaneously examined the maturational status of CMV-specific CD8 + T cells in patients with a history of CMVR. These measurements were compared in 2 groups of patients with CMVR-one with clear evidence of absent CMVprotective immunity (i.e., patients with active CMVR) and one with clear evidence of restored CMV-protective immunity (i.e., patients with CMVR clinically immunorestored by ART who were able to discontinue anti-CMV therapy without further retinitis reactivation or progression).
PATIENTS, MATERIALS, AND METHODS

Study participants.
Frozen peripheral-blood mononuclear cell (PBMC) specimens were obtained from Longitudinal Studies of the Ocular Complications of AIDS (LSOCA)-a prospective, multicenter, observational study of patients with AIDS [24, 25] . Two patient groups were studied. Group 1 (active CMVR) was composed of subjects with a white opacified retinal lesion (consistent with CMVR) or new CMVR progression (defined as movement of a retinitis border by у750 mm along a front у750 mm wide or development of a new area of retinitis у750 mm in diameter). Group 2 (immunorestored CMVR) was composed of subjects with a history of CMVR diagnosis who were no longer receiving anti-CMV treatment and had been receiving HAART for у6 months, whose absolute CD4 + T cell counts were у200 cells/mL and who had у2 years of ophthalmologic follow-up at the time of the study without receiving anti-CMV therapy or having retinitis reactivation or progression. Informed consent was obtained from all patients participating in the study. The human experimentation guidelines of the US Department of Health and Human Services and of participating institutions were followed in conducting this research.
PBMC samples. PBMCs, cryopreserved from acid citrate dextran whole blood as described elsewhere [15] , were obtained from the LSOCA specimen repository.
CMV-specific multiparameter CFC assay. For each subject, 1 aliquot of cryopreserved PBMCs were rapidly 6 10 ϫ 10 thawed into warm RPMI 1640 with 10% fetal bovine serum (Invitrogen), washed, and rested overnight in slanted 15-mL conical tubes with loosened caps in 3 mL of the same medium, in a CO 2 incubator at 37ЊC. PBMCs were then washed and resuspended for counting using the Viacount assay on a Guava Personal Cell Analysis system (Guava). Samples with !50% viability or !10% recovery were discarded.
Remaining samples were plated at -cells/mL 6 6 1 ϫ 10 2 ϫ 10 and stimulated with pp65 or IE1 peptide pools or the combined pools. Peptides (15-aa residues, overlapping by 11 aa) spanning the pp65 (SynPep) and IE-1 (Jerini AG) proteins of CMV were dissolved in dimethly sulfoxide at a concentration of 0.7 mg/ mL/peptide and used at a final concentration of 1.7 mg/mL/ peptide (1:400 dilution). For each sample, a nonstimulated control was set up. If ! cells were recovered, a single 6 4 ϫ 10 combined pp65/IE1 stimulation was set up. Data from the independent pp65 and IE1 stimulations were summed for each subject and considered as combined pp65/IE1 stimulation data. Data were background corrected by subtracting the control assay results and normalized to cytokine-expressing cells per milliliter by multiplying the percentage of cytokine-expressing cells by the absolute number of CD4 + or CD8 + T cells per milliliter.
Cells were stimulated for 6 h at 37ЊC in 0.5 mg/mL brefeldin A in a temperature-controlled plate incubator (INHECO) and held at 18ЊC after the incubation period (holding the sample at 18ЊC until staining was found to give better results than holding at 4ЊC; data not shown). The following day, cells were treated with 2 mmol/L EDTA, then washed and resuspended in PBS with 0.5% bovine serum albumin (BSA). Cells were then stained with CD4-AmCyan, CD8-Alexa 700, CD45RA-PE-CY7, CD27-APC, and CD28-APC-CY7 (all from BD Biosciences) in the presence of 5 mg/mL ethidium monoazide bromide (EMA; Molecular Probes) and incubated for 50 min in the dark at 4ЊC followed by exposure to a 40-W fluorescent light for 10 min at room temperature, to cross-link the EMA. Cells were washed and then fixed and permeabilized by 10-min incubation in FACS Lyse and 10 min incubation in FACS Perm (both from BD Biosciences). Cells were then washed and stained with IFN-g-fluorescein isothiocyanate, IL-2-phyco- figure 3A . Figure 3B shows the absolute numbers of each subpopulation plotted in approximate order of differentiation, with the presumed earliest subpopulations to the left and the more mature subpopulations to the right. Because these data suggested that CD27 and CD28 expression by CMV-specific cells may be important in immune recovery from CVMR, we examined the relative importance of each marker to identify parameters that might not require 9-color analysis. We compared expression of total CD28, CD27, and both CD27 and CD28 on CMV-specific CD8 + cells stimulated with combined pp65/IE1 and observed that group 2 had significantly higher numbers than group 1 of all 3 marker combinations-total CD8 + IFN-g T cells above the respective cutoff values, whereas 29 (85%) of 34 of the immunorestored patients with CMVR had at least 1 positive value, and 25 (74%) had positive results by at least 2 of these measurements. These CMV-specific assays are more likely to have clinical utility than measurements with higher false-positive rates because, from a treatment perspective, there is more potential for irreversible harm in not treating patients who will develop active CMVR (i.e., loss of vision) than in Only subjects with 150 cytokine-positive events were included in the analysis. P values were adjusted for multiple comparisons using the Bonferroni correction. *Borderline P value in the .0019-.01 range for any pairwise comparison (Mann-Whitney U test); ** . P ! .0018
T cells expressing both interferon (IFN)-g and interleukin (IL)-2 (A) or IFN-g alone (B) and of CD8 + T cells expressing both IFN-g and IL-2 (C) or IFN-g alone (D)
treating patients who will not develop active CMVR (i.e., cost and toxicities of treatment).
DISCUSSION
The availability of cryopreserved PMBCs from subjects with active CMVR and quiescent CMVR with restored CMV-protective immunity after HAART, combined with multicolor flow cytometric assays, enabled testing of the hypothesis that recovery from AIDS-related CMVR is mediated, in part, by CMVspecific CD4 + and CD8 + T cells capable of promoting antigenspecific CD8 + T cell proliferation. A 9-color CFC assay was used to simultaneously measure the expression of IFN-g and IL-2 and to characterize the maturational phenotype of CMVspecific CD8 + T cells. Although many published studies have compared either CD4 + or CD8 + T cell responses in patients with active and immunorestored CMVR, only 2 that we know of have compared CMV-specific CD4 + and CD8 + T cell responses in the same patients [19, 20] , and neither report examined IL-2 expression or the maturational status of cytokinepositive CD8 + T cells. Consistent with most previous reports, we observed that patients with active retinitis had significantly lower CD4 + and CD8 + T cell IFN-g responses than patients who were clinically immunorestored [14] [15] [16] [18] [19] [20] . However, we also observed significantly lower numbers of CMV-specific T cells that also expressed IL-2 in subjects with active CMVR, findings not previously reported in the context of AIDS-related CMV disease. These findings are consistent with both murine CMVR (MCMVR) and HIV studies. In experimental MCMVR, systemic immunotherapy with IL-2 provided protection against murine AIDS-related MCMVR by stimulation of the perforinmediated pathway of cytotoxicity used by NK cells and cytotoxic CD8 + T cells to kill virus-infected cells [26] . Furthermore, lack of HIV-specific CD4 + T cells from HIV disease progressors, compared with those from nonprogressors, to proliferate [29, 30] . CMV-specific CD8 + IL-2 + T cells may play a similar role in patients with AIDS with CMV end-organ disease. Among specimens stimulated with individual pp65 or IE1 pools, we observed significantly higher pp65-specific CD4 + T cell responses among the immunorestored CMVR group, whereas both groups lacked an IE1-specific CD4 + T cell response. In contrast, although there was no significant difference between the 2 groups in the number of CD8 + T cells that responded to pp65, the immunorestored group had higher numbers of CD8 + T cells that responded to IE. This latter finding is consistent with that of Sacre et al., who observed a broader diversity of CD8 + T cell IFN-g responses to IE1 peptides by ELISPOT assay in subjects with CMVR who had been immunorestored by HAART within 2 years than in patients with active CMV endorgan disease [16] . IE1-dominant CD8 + T cell IFN-g responses have also been reported to be associated with protection from developing CMV disease in HIV-negative transplant recipients [21] . We also recently reported that CMV Towne vaccine induces an IE1-dominant CD8 + T cell IFN-g and proliferation response [31] . This vaccine, although not capable of preventing infection, was able to reduce the incidence and severity of CMV disease in renal transplant recipients [32] . IE1 is one of the first CMV proteins expressed after cell infection [33] , and expression of IE1 on the surface of recently infected cells in the context of major histocompatibility complex class I may allow infected cells to be killed before they produced new CMV virions, thus reducing the spread of CMV and promoting recovery from CMV disease.
In examining maturational phenotypes of CMV-specific, cytokine-expressing CD8 + T cells, we observed that cells with an early maturational phenotype (CD27  + CD28  + CD45RA  + and  CD27   +   CD28   +   CD45RA Ϫ ) were detectable in immunorestored patients with CMVR and were essentially absent in patients with active CMVR. In addition, there was a marginally significant increase in the CD27 Ϫ CD28 + CD45RA Ϫ population. As CD8 + T cells mature from naive to memory and effector, they are thought to sequentially down-regulate CD45RA, CD27, and then CD28 [34] [35] [36] . Our findings are similar to those of Sacre et al., in that most CMV-specific, cytokine-expressing CD8 + T cells from both groups had a mature CD27 Ϫ CD28 Ϫ phenotype, and CD8 + T cells from immunorestored subjects with quiescent CMVR contained expanded populations of CD27 + CD28
+ and CD27 Ϫ CD28 + cells, which were absent in patients with active CMVR [16] . In the current study, the addition of CD45RA did not appear to further differentiate between these 2 groups.
Thus, both immature CD28 + CD8 + T cells capable of making IL-2 (to drive maturation and sustain the CTL response) and mature cytotoxic CD28
Ϫ CD8 + T cells may be required for reconstitution of CMV-protective immunity in AIDS-related CMVR.x T cells lacking the costimulatory molecule CD28 have a greatly reduced potential for replication, reduced telomerase activity, and reduced telomere length [34, 37, 38] . CD27
+ T cells may retain the ability to expand and produce IL-2 in response to antigenic stimulation but may also require CD4 + T cell help. In the absence of less mature populations, the CD8 + T cell response against CMV may not be adequate to contain the replication and spread of CMV. This hypothesis is supported by data from Bronte et al., who reported the disappearance of CMV-specific CD4 + T cells 1 year before the onset of CMV end-organ disease in patients with AIDS [19] . Treatment of patients with AIDS-related CMVR by HAART may allow recovery of CMV-specific CD4 + T cells (presumably depleted by HIV-1 infection) as HIV-1 replication is suppressed. Our findings suggest that such immune restoration is associated with expression of both IFN-g and IL-2 by CMVspecific CD4 + and CD8 + T cells and with expression of CD28 by CMV-specific CD8 + T cells. However, the current study does not rule out the possibility that the observed differences between the groups may be a consequence of differences in immunity to CMV. To determine whether the populations that were associated with immune restoration are actively involved in maintaining immunity, a prospective case-control study will need to be performed using PBMCs obtained before case patients develop incident CMVR or progression or reactivation of prevalent CMVR.
In conclusion, we identified 3 CMV-specific T cell parameters that, when combined, discriminated better between patients with active and immunorestored CMVR than CMV-specific T cell parameters reported in the past. CD8 absent in all 24 patients with active CMVR, whereas 29 (85%) of 34 of the patients with immunorestored CMVR had a positive value by at least 1 of these parameters. Because progression of untreated CMVR causes irreversible loss of retina and because the drugs used to treat CMVR have considerable risk of toxicity and are very expensive, there is a need for clinicians to know when it is optimal to initiate, discontinue, or reinstitute anti-CMV therapy. The CMV-specific T cell measurements identified in this exploratory analysis can now be tested in observational studies for their predictive value and potential clinical utility in defining CMV-protective immunity and guiding clinical management for HIV-infected patients with a history of CMVR or at risk for developing CMVR. 
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